Cargando…
SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
Autores principales: | Patoulias, Dimitrios, Michailidis, Theodoros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396330/ https://www.ncbi.nlm.nih.gov/pubmed/36062276 http://dx.doi.org/10.14218/JCTH.2022.00278 |
Ejemplares similares
-
COVID-19 Drug Treatment in China
por: Fan, Linzi, et al.
Publicado: (2020) -
Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment
por: Shi, Ke, et al.
Publicado: (2021) -
Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey
por: Sözmen, Kaan, et al.
Publicado: (2016) -
Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment
por: Aryal, Madan Raj, et al.
Publicado: (2020) -
Role of Complementary and Alternative Medicine in Prevention and Treatment of COVID-19: An Overhyped Hope
por: Shankar, Abhishek, et al.
Publicado: (2020)